178 Chapter 5 22. Mercier A, Auger-Aubin I, Lebeau JP, Royen P Van, Peremans L. Understanding the prescription of antidepressants: a qualitative study among French GPs. BMC Family Practice. 2011;12(1):1–9. 23. Dumesnil H, Cortaredona S, Verdoux H, Sebbah R, Paraponaris A, Verger P. General Practitioners’ Choices and Their Determinants When Starting Treatment for Major Depression: A Cross Sectional, Randomized Case-Vignette Survey. Scott JG, editor. PLoS ONE. 2012 Dec 18;7(12):e52429. 24. Morrison J, Anderson MJ, Sutton M, Munoz-Arroyo R, McDonald S, Maxwell M, et al. Factors influencing variation in prescribing of antidepressants by general practices in Scotland. British Journal of General Practice. 2009;59(559):88–93. 25. Sibbald B, Addington-Hall J, Brenneman D, Freeling P. Investigation of whether on-site general practice counsellors have an impact on psychotropic drug prescribing rates and costs. British Journal of General Practice. 1996;46(403):63–7. 26. Estrela M, Herdeiro MT, Ferreira PL, Roque F. The Use of Antidepressants, Anxiolytics, Sedatives and Hypnotics in Europe: Focusing on Mental Health Care in Portugal and Prescribing in Older Patients. International Journal of Environmental Research and Public Health. 2020 Nov 19;17(22):8612. 27. ERS. Acesso a serviços de saúde mental nos Cuidados de Saúde Primários. 2023; 28. Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Ebert D, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023 Feb 1;22(1):105–15. 29. Plessen CY, Karyotaki E, Miguel C, Ciharova M, Cuijpers P. Exploring the efficacy of psychotherapies for depression: a multiverse meta-analysis. BMJ mental health. 2023 Feb;26(1):e300626. 30. Cuijpers P, Quero S, Noma H, Ciharova M, Miguel C, Karyotaki E, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World psychiatry : official journal of the World Psychiatric Association (WPA). 2021 Jun 1;20(2):283–93. 31. Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Papola D, et al. Psychological treatment of depression: A systematic overview of a “Meta-Analytic Research Domain.” Journal of affective disorders. 2023 Aug 15;335:141–51. 32. Andersson SJ, Troein M, Lindberg G. Conceptions of depressive disorder and its treatment among 17 Swedish GPs. A qualitative interview study. Family Practice. 2001 Jan 1;18(1):64–70. 33. Van Schaik DJF, Klijn AFJ, Van Hout HPJ, Van Marwijk HWJ, Beekman ATF, De Haan M, et al. Patients’ preferences in the treatment of depressive disorder in primary care. General Hospital Psychiatry. 2004;26(3):184–9. 34. Haddad M, Menchetti M, Walters P, Norton J, Tylee A, Mann A. Clinicians’ attitudes to depression in Europe: a pooled analysis of Depression Attitude Questionnaire findings. Family Practice. 2012 Apr 1;29(2):121–30. 35. Bell A, Fairbrother M, Jones K. Fixed and random effects models: making an informed choice. Quality & Quantity. 2019 Mar 7;53(2):1051–74. 36. Bell A, Jones K. Explaining Fixed Effects: Random Effects Modeling of Time-Series Cross-Sectional and Panel Data. Political Science Research and Methods. 2015 Jan 1;3(1):133–53. 37. Fairbrother M. Trust and Public Support for Environmental Protection in Diverse National Contexts. Sociological Science. 2016;3:359–82. 38. Wang PS, Aguilar-Gaxiola S, AlHamzawi AO, Alonso J, Andrade LH, Angermeyer M, et al. Treated and untreated prevalence of mental disorder worldwide. Oxford textbook of community mental health. 2011;50– 66. 39. Caldas de Almeida JM, Xavier M, Cardoso G, Pereira MG, Gusmão R, Corrêa B. Estudo epidemiológico nacional de saúde mental. Lisboa Faculdade de Ciê ncias Médicas, da Universidade Nova de Lisboa. 2013;1. 40. Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, et al. Depressive disorders in Europe: prevalence figures from the ODIN study. British Journal of Psychiatry. 2001 Oct 2;179(4):308–16. 41. Comissão Técnica de Acompanhamento da Reforma da Saúde Mental. Relatório da Avaliação do Plano Nacional de Saúde Mental 2007-2016 e propostas prioritárias para a extensão a 2020. 2017. 42. Lewer D, O’reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. 2022; 43. Caldas AC, Torre C, Castelão J, Monteiro M da PL, Lopes P, Batista T, et al. Sem mais tempo a perder-Saúde mental em Portugal: um desafio para a próxima década. CNS http://www cns minsaude pt/wp-content/ uploads/2019/12/SEM-MAIS-TEMPO-A-PERDER pdf Accessed. 2020;11.
RkJQdWJsaXNoZXIy MjY0ODMw